Extrapolation of experimental safety data to humans: The interleukin-6 case

Clinical Immunology and Immunopathology

Volumn 83, Issue 1, 1997, Pages 15-17

  Kammuller M ^a   Ryffel, B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6;

ANEMIA; CONFERENCE PAPER; DRUG INDUCED DISEASE; FEVER; HEADACHE; HEMATOPOIESIS; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOXICITY;

EID: 0031127540     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.4305     Document Type: Conference Paper

References (16)

1. 1. Kishimoto, T., The biology of interleukin-6. Blood 74, 1-10, 1989.
2. 2. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T., Interleukin-6 family of cytokines and gp130. Blood 86, 1243-1254, 1995.
3. 3. Hirano, T., Akira, S., Taga, T., and Kishimoto, T., Biological and clinical aspects of interleukin 6. Immunol. Today 11, 443-449, 1990.
4. 4. Van Snick, J., Interleukin-6: An overview. Annu. Rev. Immunol. 8, 253-278, 1990.
5. 5. Le, J., and Vilcek, J., Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute-phase protein response. Lab. Invest. 61, 588-602, 1989.
6. 6. Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, M., Ohno, S., Hirano, T., and Kishimoto, T., IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 86, 7547-7551, 1989.
7. 7. Ryffel, B., Kammuller, M., Robison, R., and Myers, L., Pathology induced by interleukin-6. Toxicol. Lett. 311-319, 1992.
8. 8. Ryffel, B., Mihatsch, M. J., and Woerly, G., Pathology induced by interleukin-6. Int. Rev. Exp. Pathol. 34, 79-89, 1993.
9. 9. Kammüller, M. E., Recombinant human interleukin-6: Safety issues of a pleiotropic growth factor. Toxicology 105, 91-107, 1995.
10. 10. Ryffel, B., Car, B. D., Gunn, H., Roman, D., Hiestand, P., and Mihatsch, M. J., Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice. Am. J. Pathol. 144, 927-937, 1994.
11. 11. Myers, L. A., Boyce, J. T., and Robison, R. L., The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey. Toxicology 101, 157-166, 1995.
12. 12. Klug, S., Neubert, R., Stahlmann, R., Thiel, R., Ryffel, B., Car, B. D., and Neubert, D., Effects of recombinant human interleukin 6 (rhIL-6) in marmosets (Callithrix jacchus). 1. General toxicity and hematological changes. Arch. Toxicol. 68, 619-631, 1994.
13. 13. Ryffel, B., Car, B. D., Woerly, G., Weber, M., DiPadova, F., Kammuller, M., Klug, S., Neubert, R., and Neubert, D., Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate -the marmoset. Blood 83, 2093-2102, 1994.
14. 14. Scheid, C., Young, R., McDermott, R., Fitzsimmons, L., Scarffe, J. H., and Stern, P. L., Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 38, 119-126, 1994.
15. 15. Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D., and Rosenberg, S. A., A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 15, 292-302, 1994.
16. 16. van Gameren, M. M., Willemse, P. H., Mulder, N. H., Limburg, P. C., Groen, H. J., Vellenga, E., and de Vries, E. G., Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 84, 1434-1441, 1994.